The "Com-COV2" study will include 1,050 adults 50 years of age or older who received their first vaccination during the prior eight to 12 weeks. Volunteer study participants will receive one of four different vaccines as a second dose, 350 of whom will be administered NVX-CoV2373. The research will compare the immune system responses from those who receive a heterologous regimen to those who receive a homologous regimen.

In addition, NVX-CoV2373 continues to be evaluated in phase III trials, one in the U.K that demonstrated efficacy of 96.4% against the original strain of SARS-CoV-2 and 89.7% overall, and one in the U.S. and Mexico (the Prevent-19 trial) that began in December 2020. It is also being tested in two ongoing phase II studies that began in August 2020: a phase IIB trial in South Africa that demonstrated 48.6% efficacy against a newly emerging escape variant, and a phase I/II continuation in the U.S. and Australia.

GSK to provide services for Novavax's COVID-19 vaccine in the U.K.
GlaxoSmithKline (GSK) has signed an agreement in principle to support manufacturing of up to 60 million doses of Novavax's NVX-CoV2373 COVID-19 vaccine...

Novavax confirms efficacy against U.K., South African SARS-CoV-2 strains
Novavax's SARS-CoV-2 vaccine candidate NVX-CoV2373 has a 96.4% efficacy against mild, moderate, and severe disease caused by the original COVID-19 strain,...

Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...

Novavax to supply Covax with 1.1B COVID-19 vaccine doses
Novavax announced a memorandum of understanding with Gavi, the Vaccine Alliance, to provide 1.1 billion cumulative doses of its COVID-19 vaccine...

Novavax to supply Switzerland with 6M doses of COVID-19 vaccine
Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.